This site is intended for health professionals only

Thursday 22 August 2019
LatestNews
Share |

Latest News

Dupilumab reaches primary and secondary endpoints in paediatric trial

Thursday 8th August 2019
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
 
The topline data show that for children with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-...
Thu, 11 Jul 2019
The results of joint studies by Sobi™ and Sanofi were presented at ISTH 2019, the 27th Congress of the International Society on Thrombosis and Haemostasis, in Melbourne, Australia, on 7, 8 and 9 July 2019.
Thu, 11 Jul 2019
In the first study of its kind, researchers from the University of Surrey investigated nurses’ awareness of cancer warning signs, cancer screening and the frequency of discussions held with patients about early cancer diagnosis in eight countries across the world
Tue, 2 Jul 2019
A Norwegian study has an increased risk of developing haematological cancers in non-MS siblings of MS patients, compared with both MS patients and the general population
Mon, 1 Jul 2019
The test looks at 19 different variants of the DPYD gene that indicate susceptibility with the toxicity of these drugs; DPYD activity is important as it normally acts to breakdown 5-FU.
Thu, 20 Jun 2019
Crohn’s & Colitis UK and IBD UK campaign to promote better care for everyone with IBD and provide greater access to psychological and dietetic support and more timely diagnosis
Thu, 20 Jun 2019
The purpose of the study was to assess the drug’s pharmacokinetics, efficacy and safety for treatment of MAS and to confirm the proposed dose regimen
Tue, 18 Jun 2019
This approval is based on data from the Phase III SOLO-1 trial, which showed that Lynparza, after a median follow-up of 40.7 months, lowered the risk of disease progression or death by 70% than with placebo